Syngene International Ltd earnings miss, Revenue beats in Q2
Investing.com - Syngene International (NS:SYNN) Ltd reported on Thursday second quarter {{erl-958336||earnings that missed analysts' forecasts and revenue that topped expectations. ...
Buy
or
Syngene International Ltd News & Analysis
-
-
5 Pharma Stocks that Have Surged in April Because of Remdesivir
By Aditya Raghunath Investing.com -- Remdesivir is an anti-viral drug used to treat COVID-19. It is one of the most sought-after during the second wave of the pandemic in India. It has been...
-
UPDATE 1-Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges
(Adds details, quotes from CEO interview, background)By Anuron Kumar MitraBENGALURU, April 28 (Reuters) - India's Syngene International Ltd SYNN.NS aims to supply half-a-million vials of...
-
Syngene targets delivering 500,000 vials of remdesivir in India in May - executive
BENGALURU, April 28 (Reuters) - India's Syngene International Ltd SYNN.NS is aiming to deliver half a million vials of COVID-19 drug remdesivir through its distribution partners to the...
-
BRIEF-Syngene And Deerfield Discovery And Development Sign 5-Year Strategic Collaboration
Nov 19 (Reuters) - Syngene International Ltd SYNN.NS :* SYNGENE AND DEERFIELD DISCOVERY AND DEVELOPMENT (3DC) SIGN 5-YEAR STRATEGIC COLLABORATION...
-
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
BENGALURU, Aug 13 (Reuters) - Zydus Cadila CADI.NS on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following...
-
Mylan to launch generic remdesivir version in India at $64 per 100 mg vial
BENGALURU, July 6 (Reuters) - Drugmaker Mylan NV MYL.O said on Monday it would launch its generic version of Gilead Sciences Inc 's GILD.O COVID-19 treatment remdesivir in India this month...
-
BRIEF-Syngene International Ties Up With HiMedia Laboratories To Manufacture ELISA Test Kits For COVID-19
June 2 (Reuters) - Syngene International Ltd SYNN.NS :* TIES UP WITH HIMEDIA LABORATORIES TO MANUFACTURE ELISA TEST KITS FOR COVID-19...
-
BRIEF-Syngene International Temporarily Halts Activities At Facilities
March 25 (Reuters) - Syngene International Ltd SYNN.NS :* TEMPORARY SUSPENSION OF RESEARCH ACTIVITIES AT FACILITIES AT BANGALORE SEZ AND HYDERABAD...
-
BRIEF-Syngene International Appoints Jonathan Hunt As CEO
Jan 22 (Reuters) - Syngene International Ltd SYNN.NS :* SYNGENE INTERNATIONAL LTD SAYS APPOINTS JONATHAN HUNT AS MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER* SYNGENE INTERNATIONAL LTD...
-
BRIEF-India's Syngene International Dec Quarter Consol Profit Rises
Jan 22 (Reuters) - Syngene International Ltd SYNN.NS :* DEC QUARTER CONSOL PROFIT 918 MILLION RUPEES VERSUS 870 MILLION RUPEES YEAR AGO* DEC QUARTER CONSOL REVENUE FROM OPERATIONS 5.19...
-
BRIEF-Syngene International Appoints Sibaji Biswas As CFO
Dec 2 (Reuters) - Syngene International Ltd SYNN.NS :* APPOINTMENT OF SIBAJI BISWAS AS THE CHIEF FINANCIAL OFFICER OF THE...
-
BRIEF-India's Syngene International Reports Rise In Sept Qtr Net Profit
Oct 22 (Reuters) - Syngene International Ltd SYNN.NS :* SEPT QUARTER NET PROFIT 1.28 BILLION RUPEES VERSUS 783 MILLION RUPEES YEAR AGO* SEPT QUARTER REVENUE FROM OPERATIONS 4.65 BILLION...
-
BRIEF-India's Syngene International Dec-Qtr Profit Rises
Jan 22 (Reuters) - Syngene International Ltd SYNN.NS :* DEC QUARTER CONSOL PROFIT 870 MILLION RUPEES VERSUS 820 MILLION RUPEES YEAR AGO* DEC QUARTER CONSOL REVENUE FROM OPERATIONS 4.67...
-
BRIEF-Syngene International COO Manoj Nerurkar To Step Down
Sept 25 (Reuters) - Syngene International Ltd SYNN.NS :* SAYS MANOJ NERURKAR, CHIEF OPERATING OFFICER, WILL STEP DOWN FROM HIS ROLE WITH EFFECT FROM 1ST OCT 2018...
-
BRIEF-Syngene International Expands Collaboration With Baxter Healthcare Corp
July 23 (Reuters) - Syngene International Ltd SYNN.NS :* SAYS EXPANDED SCOPE OF ITS RESEARCH AND DEVELOPMENT COLLABORATION WITH BAXTER HEALTHCARE CORPORATION* AS PART OF EXPANSION, SYNGENE...
-
BRIEF-India's Syngene International Announces Partnership With Zumutor Biologics
May 30 (Reuters) - Syngene International Ltd SYNN.NS :* ANNOUNCES PARTNERSHIP WITH ZUMUTOR BIOLOGICS FOR BIOTHERAPEUTIC ANTIBODY DISCOVERY SERVICES Further company coverage:...
-
BRIEF-Syngene International Enters Non-Exclusive Partnering Agreement With Zumutor Biologics
May 30 (Reuters) - Syngene International Ltd SYNN.NS :* SYNGENE INTERNATIONAL - ENTERED INTO NON-EXCLUSIVE PARTNERING AGREEMENT WITH ZUMUTOR BIOLOGICS...
-
BRIEF-Syngene International Says Promoter Biocon Proposes To Divest Part Of Its Shareholding In Co
May 15 (Reuters) - Syngene International Ltd SYNN.NS :* SAYS PROMOTER BIOCON PROPOSES TO DIVEST PART OF ITS SHAREHOLDING IN CO...
-
BRIEF-India's Syngene International March-Qtr Profit Rises
April 25 (Reuters) - Syngene International Ltd SYNN.NS :* MARCH QUARTER PROFIT 843 MILLION RUPEES VERSUS PROFIT OF 784 MILLION RUPEES YEAR AGO* MARCH QUARTER REVENUE FROM OPERATIONS 4.09...
-
BRIEF-Syngene International Signs Research And Development Agreement With GSK
March 26 (Reuters) - Syngene International Ltd SYNN.NS :* SAYS CO SYNGENE INTERNATIONAL SIGNS RESEARCH AND DEVELOPMENT AGREEMENT WITH GSK* SAYS CO'S SCIENTISTS TO WORK WITH GSK TO...
-
BRIEF-India's Syngene International Dec-Qtr Profit Rises
Jan 23 (Reuters) - Syngene International Ltd SYNN.NS :* DEC QUARTER PROFIT 819 MILLION RUPEES VERSUS PROFIT 744 MILLION RUPEES YEAR AGO* DEC QUARTER REVENUE FROM OPERATIONS 3.88 BILLION...
-
BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration
Nov 14 (Reuters) - Syngene International SYNN.NS :* Bristol-Myers Squibb and Syngene International expand ongoing research collaboration* Says collaboration with Bristol-Myers Squibb...
-
BRIEF-Syngene International expands collaboration with Bristol-Myers Squibb
Nov 14 (Reuters) - Syngene International Ltd SYNN.NS :* Says expanded collaboration with Bristol-Myers Squibb* Nnext phase of partnership will see addition of facility to support future...
-
BRIEF-India's Syngene International Sept-qtr profit rises 3 pct
Oct 25 (Reuters) - Syngene International Ltd SYNN.NS* Sept quarter net profit 769 million rupees versus profit of 747 million rupees last year* Sept quarter revenue from operations 3.35...
-
BRIEF-Syngene International says Silver Leaf Oak Mauritius cuts stake in co
Oct 5 (Reuters) - Syngene International Ltd SYNN.NS* Says Silver Leaf Oak Mauritius cuts stake in co by 2.12 percent to 7.80 pct...
-
BRIEF-Syngene International confident that impact of fire incident of last yr to taper off in coming qtrs
July 27 (Reuters) - Syngene International Ltd SYNN.NS* Says confident that the impact of the fire incident of last year will taper off in the coming quarters* Says maintain expectation...
-
BRIEF-India's Syngene International June-qtr profit rises about 4 pct
July 27 (Reuters) - Syngene International Ltd SYNN.NS* June quarter profit 620 million rupees versus 598 million rupees last year* June quarter total income 3.08 billion rupees versus 2.90...
-
BRIEF-Syngene International & Herbalife partner to establish nutrition R&D lab in India
March 2 (Reuters) - Syngene International Ltd SYNN.NS :* Says Herbalife (NYSE:HLF) nutrition partners with Syngene to establish nutrition research and development lab in India* Says...
-
BRIEF-Syngene International Dec qtr profit falls about 4 pct
Jan 24 (Reuters) - Syngene International Ltd SYNN.NS* Syngene International Ltd - dec quarter net profit 744 million rupees* Syngene International Ltd - dec quarter net sales 3.24 billion...
-
BRIEF-Syngene International says no loss of life at lab fire
Dec 13 (Reuters) - Syngene International Ltd SYNN.NS * Syngene International Ltd says fire last night at one laboratory building; no loss of life or any injury Source text - Further...
-
BRIEF-Syngene International Sept qtr profit up about 54 pct
Oct 20 (Reuters) - Syngene International Ltd SYNN.NS* Syngene International Ltd - sept quarter net profit 747 million rupees* Syngene International Ltd - sept quarter net sales 2.95...
-
BRIEF-Syngene International buys systems biology, pharma services practice of Strand Life Sciences
Sept 21 (Reuters) - Syngene International Ltd SYNN.NS : * Syngene International closes deal with Strand Life Sciences to purchase systems biology and pharma services practice * Financial...
-
BRIEF-Syngene International commissions dedicated R&D centre for Amgen
Sept 6 (Reuters) - Syngene International Ltd SYNN.NS :* Syngene International commissions dedicated research and development centrefor Amgen (NASDAQ:AMGN)* Further company coverage...
-
BRIEF-Syngene International June-qtr profit rises
July 21 (Reuters) - Syngene International Ltd SYNN.NS :* June-quarter net profit 598 million rupees versus 466 million rupees lastyear* June-quarter net sales 2.69 billion rupees versus...
-
BRIEF-Syngene International sets interim dividend at 1 rupee per share
March 11 (Reuters) - Syngene International Ltd SYNN.NS :* Sets interim dividend at a rate of 10% i.e. 1 rupee per...
-
BRIEF-Syngene International Dec-qtr net profit rises
Jan 21 (Reuters) - Syngene International Ltd SYNN.NS :* December-quarter net profit 588 million rupees versus 448 million rupees yearago* December-quarter net sales 2.75 billion rupees...
-
BRIEF-Syngene appoints Jonathan Hunt as CEO - Designate
Jan 4 (Reuters) - Syngene International Ltd SYNN.NS :* Syngene appoints Jonathan Hunt as CEO - designate* Hunt will take charge after retirement of current CEO Peter...
-
Market turbulence rattles small Indian IPOs as bigger deals loom
By Abhishek Vishnoi and Karen Rebelo MUMBAI, Sept 2 (Reuters) - A lukewarm response to two small initial public offerings (IPOs)in India this week has raised concerns about the impact of...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
